Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes-Reference-Cited by-同舟云学术

Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes

Published:2022-07 Issue: Volume:63 Page:103892
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Hestvik Anne Lise K.^ORCID,Frederiksen Jette Lautrup,Nielsen Helle Hvilsted,Torkildsen Øivind,Eek Camilla,Huang-Link Yumin,Haghighi Sara,Tsai Jon A.,Kant Matthias

Funder

Sanofi

Javna Agencija za Raziskovalno Dejavnost RS

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference25 articles.

1. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease;Atkinson;Health Qual. Life Outcomes,2004

2. On Behalf Of The Teri-Real Investigators. Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study;Bencsik;Pharmaceuticals (Basel),2022

3. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry;Braune;J. Neurol.,2018

4. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS ): a multicentre , double-blind , phase 3 , randomised , placebo-controlled trial;Chitnis;Lancet Neurol.,2021

5. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial;Confavreux;Lancet Neurol,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role;Frontiers in Immunology;2024-03-13

2. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study;Neurology and Therapy;2023-10-20

3. Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study;Neurology Perspectives;2023-10

4. Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis;Expert Review of Neurotherapeutics;2023-06-29